Burden of Herpes Zoster in selected immunocompromised populations in the German Pharmacoepidemiological Research Database (GePaRD)

First published: 25/01/2017

Last updated: 29/03/2024

Study | Finalised

Administrative details

EU PAS number

EUPAS17402

Study ID

17403

DARWIN EU® study

No

Study countries

Germany

Study description

Based on data from statutory health insurance providers, the study investigates the incidence of herpes zoster in patients with different severities of immunosuppression. Besides, frequencies of complications and different aspects of healthcare resource utilisation are examined for herpes zoster patients stratified by severity of immunosuppression.

Study status

Finalised

Research institutions and networks

Institutions

Leibniz Institute for Prevention Research and Epidemiology - BIPS

Germany

First published: 29/03/2010

Last updated: 30/03/2026

Institution | Not-for-profit | ENCePP partner

Contact details

Study institution contact

Oliver Riedel riedel@leibniz-bips.de

Study contact

riedel@leibniz-bips.de

Primary lead investigator

Oliver Riedel

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 03/04/2015

Actual: 01/06/2015

Study start date

Planned: 20/07/2015

Actual: 01/12/2015

Data analysis start date

Planned: 10/08/2015

Actual: 04/01/2016

Date of final study report

Planned: 10/06/2016

Actual: 30/11/2016

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

GlaxoSmithKline Biologicals S.A.

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Data collection methods:

Secondary use of data

Main study objective:

To estimate the incidence of herpes zoster and its complications in immunocompromised subjects, aged 18 years and above, overall and stratified by sex, age group, and type of immunocompromising disease or therapy.

Study Design

Non-interventional study design

Cohort

Cross-sectional

Study drug and medical condition

Medical condition to be studied

Herpes zoster

Population studied

Short description of the study population

Patients aged 18 years and above with different severities of immunosuppression.

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Special population of interest

Immunocompromised

Estimated number of subjects

1.260.000

Study design details

Outcomes

Incidence of herpes zoster. Prevalence of herpes zoster complications and frequencies of hospitalisations, physician visits, and treatments with antivirals and analgesics.

Data analysis plan

A cross-sectional design will be used to identify patients with different severities of immunosuppression for the years 2006-2012 based on immunocompromising diseases and drug treatments. A cohort design will be used to calculate annual incidence rates of herpes zoster for the years 2006-2012, stratified by age, sex, and severity of immunosuppression and to analyse the prevalence of herpes zoster complications, physician visits, hospitalisations, and antiviral and analgesic treatments.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

German Pharmacoepidemiological Research Database

Data sources (types)

Administrative healthcare records (e.g., claims)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown